Related Experiment Video
Updated: May 22, 2025

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach
Published on: June 11, 2017
Physiologically based pharmacokinetic modeling of tapentadol in children to support pediatric dose selection
Zilong Wang1, Yujie Yang2, Zhihai Cao1
1School of Pharmacy, Anhui Medical University, Hefei 230601, China; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
Insights
This study developed a physiologically based pharmacokinetic (PBPK) model to establish safe and effective tapentadol dosing regimens for pediatric patients across all age groups. The model ensures accurate tapentadol dosage recommendations for children.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Pediatric Pharmacology
- Computational Modeling
Background:
- Tapentadol is an effective opioid analgesic for moderate to severe pain unresponsive to non-opioid analgesics.
- Optimizing pediatric dosing is crucial due to physiological differences affecting drug disposition.
- Physiologically based pharmacokinetic (PBPK) modeling offers a robust approach for pediatric drug dosage refinement.
Purpose of the Study:
- To develop and validate a PBPK model for tapentadol disposition in pediatric populations.
- To characterize tapentadol pharmacokinetics (PK) across diverse pediatric age groups.
- To establish refined, age-specific dosing strategies for tapentadol oral solution in children.
Main Methods:
- An adult PBPK model was adapted for pediatric use by scaling anatomical and physiological parameters.
- Model validation involved comparing simulated plasma concentrations against empirical data.
- Dosages were translated from adult to pediatric populations, with weight-adjusted doses assessed for different age strata.
Main Results:
- The PBPK model accurately predicted tapentadol PK parameters in pediatric populations, with a mean absolute prediction error (MAPE) below 0.45.
- Predicted to observed PK parameter ratios for adults ranged from 0.80 to 1.40.
- A validated fixed-dose regimen for tapentadol oral solution was established for children from 0 to 18 years.
Conclusions:
- The developed PBPK model successfully characterized tapentadol disposition in pediatric patients.
- The study provides evidence-based, fixed-dose recommendations for tapentadol oral solution across pediatric age groups.
- Findings support the utility of PBPK modeling for optimizing pediatric drug dosing, especially for drugs with complex metabolic pathways.
Abstract:
Tapentadol, an effective opioid analgesic, is indicated for the treatment of pain that cannot be managed with non-opioid medications. This study employed a physiologically based pharmacokinetic (PBPK) model to characterize the disposition of tapentadol in children across different age groups and to refine pediatric dosing strategies. Initially, an adult PBPK model was developed using the 'middle-out' strategy, which was then adjusted by scaling anatomical and physiological parameters to apply it to pediatric populations. The model's precision was confirmed by comparing the simulated plasma concentrations in a virtual population with empirical data. Utilizing this model, we translated dosages from adults to children and assessed weight-adjusted dosages for children aged 2 to 18 years and those under 2 years. The ratios of predicted to observed pharmacokinetic (PK) parameters for adult tapentadol ranged from 0.80 to 1.40 with the pediatric population's predictive mean absolute prediction error (MAPE) being less than 0.45. Based on model validation, we have established the following fixed-dose regimen for tapentadol oral solution for children across various age groups: 2.5 mg for 0-1 month, 3.5 mg for 1-3 months, 5 mg for 3-6 months, 8.5 mg for 6 months to 1 year, 13 mg for 1-2 years, 20 mg for 2-6 years, 35 mg for 6-12 years, and 60 mg for 12-18 years. The results of this study may offer guidance for the clinical investigation of tapentadol in pediatric patients and for developing PBPK models for drugs undergoing multiple metabolic pathways.
Related Concept Videos
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Mechanistic Models: Overview of Compartment Models

